Skip to main content
SpringerLink
Log in

An Overview

  • Chapter
  • First Online:
Chemotherapy for Leukemia

  • 1387 Accesses

Abstract

There has been remarkable progress in chemotherapy for leukemia and related diseases, including promising studies that are still in progress. The contents consist of three parts:

  1. 1.

    Molecular targeted therapy

  2. 2.

    Novel chemotherapeutic agents, including antimetabolite analogs

  3. 3.

    Therapy targeting leukemic stem cells

In this chapter, an overview of these drugs presented in this book is briefly described.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–7.

    Article  CAS  PubMed  Google Scholar 

  2. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011;117:2358–65.

    Article  CAS  PubMed  Google Scholar 

  3. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29:487–94.

    Article  PubMed  Google Scholar 

  4. Ueda T. Update on molecular-targeted therapy in hematologic malignancies. Int J Clin Oncol. 2007;12:311–2.

    Article  PubMed  Google Scholar 

  5. Weinstein IB. Addiction to oncogenes – the Achilles heal of cancer. Science. 2002;297:63–4.

    Article  CAS  PubMed  Google Scholar 

  6. Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385:1447–59.

    Article  PubMed  Google Scholar 

  7. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–21.

    Article  CAS  PubMed  Google Scholar 

  8. Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J, et al. Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. J Clin Oncol. 2014;32:3692–6.

    Article  Google Scholar 

  9. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986;314:1065–9.

    Article  CAS  PubMed  Google Scholar 

  10. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–50.

    CAS  PubMed  Google Scholar 

  11. Shepherd FA, Rodriques Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thonqprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.

    Article  CAS  PubMed  Google Scholar 

  12. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24:2549–56.

    Article  CAS  PubMed  Google Scholar 

  13. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–28.

    Article  CAS  PubMed  Google Scholar 

  14. Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014;123:94–100. doi:10.1182/blood-2013-10-529313.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–45.

    CAS  PubMed  Google Scholar 

  16. Keating ML, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–61.

    Article  CAS  PubMed  Google Scholar 

  17. Matesan M, Rajendran J, Press OW, Maloney DG, Storb RF, Cassaday JM, et al. 90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution. Nucl Med Commun. 2014;35:1132–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016; doi:10.1056/NEJMoa1509277.

    Google Scholar 

  19. Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2014;15:57–66.

    Google Scholar 

  20. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–42.

    Article  CAS  PubMed  Google Scholar 

  21. Cohen MH, Johnson JR, Massie T, Sridhara R, McGuinn Jr WD, Abraham S, et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res. 2006;12:5329–35.

    Article  CAS  PubMed  Google Scholar 

  22. Gandhi V, Kilpatrick JM, Plunkett W, Ayres M, Harman L, Du M, et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005;106:4253–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102:2379–86.

    Article  CAS  PubMed  Google Scholar 

  24. Cihak A. Biological effects of 5-azacytidine in eukaryotes. Oncology. 1974;30:405–22.

    Article  CAS  PubMed  Google Scholar 

  25. Issa JP, Kantarjian HM, Kirkpatrick P. Azacitidine. Nat Rev Drug Discov. 2005;4:275–6.

    Article  CAS  PubMed  Google Scholar 

  26. Kantarijian H, Issa JP, Rosenfeld CS, Bennett JM, DiPersio J, Klimek V, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer. 2006;106:1794–803.

    Article  Google Scholar 

  27. Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016; doi:10.1038/ncomms10767.

    PubMed  PubMed Central  Google Scholar 

  28. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469:356–61.

    Article  CAS  PubMed  Google Scholar 

  29. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7:834–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ishikawa F, Yoshida S, Saito Y, Hijikata H, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25:1315–21.

    Article  CAS  PubMed  Google Scholar 

  31. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986;47:381–9.

    Article  CAS  PubMed  Google Scholar 

  32. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–84.

    Article  CAS  PubMed  Google Scholar 

  33. Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell. 2010;7:391–402.

    Article  CAS  PubMed  Google Scholar 

  34. Urasaki Y, Ueda T, Nakamura T. Circumvention of daunorubicin resistance by a new tamoxifen derivative, toremifene, in multidrug-resistant cell line. Jpn J Cancer Res. 1994;85:659–64.

    Article  CAS  PubMed  Google Scholar 

  35. Takemura H, Urasaki Y, Yoshida A, Fukushima T, Ueda T. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Cancer Res. 2001;61:172–7.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Fukui, 3-9-1 Bunkyo, Fukui, 910-8507, Japan

    Takanori Ueda (Vice-President)

Authors
  1. Takanori Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takanori Ueda .

Editor information

Editors and Affiliations

  1. University of Fukui, Fukui, Japan

    Takanori Ueda

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Ueda, T. (2017). An Overview. In: Ueda, T. (eds) Chemotherapy for Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-10-3332-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-3332-2_1

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-3330-8

  • Online ISBN: 978-981-10-3332-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation